
News|Videos|November 3, 2023
Frontline Treatment Options for Patients With BPDCN
Author(s)Matthew L. Ulrickson, MD
Explores the intricate decision-making process for frontline treatment in BPDCN patients, with considerations for age, fitness, and various therapeutic approaches.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5









































